Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Sanofi
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
an eight-week, multicenter, double-blind, placebo-controlled study evaluating the efficacy, safety and tolerability of one fixed 100 mg dose of Saredutant in patients with Major Depressive Disorder
To evaluate the efficacy of a 100 mg fixed dose of saredutant compared to placebo in patients with major depressive disorder
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 5 ans
Étude TCD14906 : étude de phase 1/2 évaluant la sécurité et l’efficacité de l’isatuximab en association avec du cémiplimab chez des patients ayant un myélome multiple en rechute ou réfractaire.
Le myélome multiple est une maladie de la moelle osseuse caractérisée par la multiplication dans la moelle osseuse d’un plasmocyte anormal. Le rôle des plasmocytes est de produire les anticorps (immun...
Country
France
organs
Myélomes
Specialty
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Sanofi-Aventis Deutschland GmbH (Germany)
Update Il y a 4 ans
Oxaliplatin/folinic acid/5-fluorouracil (24-hour) (OFF) plus best supportive care versus best supportive care alone (BSC) in second-line therapy of gemcitabine-refractory advanced pancreatic cancer
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Research
Update Il y a 4 ans
An open-label, multicenter study evaluating the long-term safety and efficacy of SR121463B in patients with Syndrome of Inappropriate Antidiuretic Hormone Secretion
to assess the long term safety and tolerability of SR121463B in patients with syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Research
Update Il y a 4 ans
Phase III randomized trial of concomitant radiation, cisplatin, and tirapazamine (SR259075) versus concomitant radiation and cisplatin in patients with advanced head and neck cancer
The trial will compare the efficacy and safety of concomitant chemoradiation with tirapazamine, cisplatin, and radiation versus cisplatin and radiation. Primary endpoint: Overall Survival
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Groupe
Update Il y a 4 ans
a double blind randomized study of Clopidogrel 75 mg/d versus placebo on a background of ASA 75-100 mg/d, in peripheral disease (PAD) patient receiving a unilateral below knee by-pass graft
To evaluate whether clopidogrel 75 mg o.d. versus placebo (on a background of ASA 75-100 mg/d) will lead to an increased rate of primary patency, limb salvage and survival, in patients receiving a bel...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Sanofi-aventis
Update Il y a 4 ans
Better Accepance of a Singe injection Apidra (insulin glulisine) Added to once daily Lantus (insulin glargine) versus twice daily Premixed insulin in a real Life Use Setting
To demonstrate non-inferiority of once daily injection of insuline glargine (Lantus®) plus one injection of mealtime insulin glulisine (Apidra®) at the main meal versus twice daily premixed insulin (N...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Sanofi
Update Il y a 4 ans
SANOFI AVENTIS TED10630 : Essai de phase 1-2 évaluant la tolérance, la pharmacocinétique et la pharmacodynamique d'un anticorps monoconal se fixant sur le récepteur de l'IGF (AVE1642), administré seul ou en association avec des traitements anticancéreux (sorafénib ou erlotinib), chez des patients ayant un carcinome du foie avancé. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
Dose-finding, safety, pharmacokinetic and pharmacodynamic study of AVE1642, an anti-insulin-like growth factor-1 receptor (IGF-1R/CD221) monoclonal antibody, administered as single agent and in combin...
Country
France
organs
Primitif du foie
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Sanofi-Synthelabo Recherche
Update Il y a 4 ans
A randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter study evaluating the efficacy and safety of four doses of SR147778 in obese patients
To assess the effect of SR147778 on weight loss over a period of 24 weeks when prescribed with a hypocaloric diet in obese patients.
Country
None
organs
None
Specialty
None
unknown
More information
Man Max 99 years
Genzyme, a Sanofi Company
Update Il y a 4 ans
A study to assess the renal function in young male patients with Fabry disease who have never received any specific treatment for this disease. Estudio para evaluar la función renal en varones jóvenes con enfermedad de Fabry los cuales no han recibido nunca ningún tratamiento específico
To document renal function and other Fabry disease manifestations across age in treatment-naïve, young male patients with Fabry disease. Documentar la función renal y otras manifestaciones de la...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next